

**EDITORIAL**

The 7<sup>th</sup> Multidisciplinary Conference on Drug Research, organized under auspices of Pharmaceutical Research Institute, Scientific Network: Synthesis, Structure and Therapeutic Properties of Organic Compounds (coordinated by the Institute of Organic Chemistry, Polish Academy of Sciences), Polish Pharmaceutical Society, Polish Chemical Society and Committee of Therapy and Drug Research of the Polish Academy of Science, took place in Zakopane between May 10<sup>th</sup> and 12<sup>th</sup> 2010. The MKNOL conference, as it is known by Polish acronym, constitutes a series of events, which commenced in 2000, stressing from the beginning the need for multidisciplinary communication of all researchers interested in scientific progress for betterment of human life, by application of medicinal compounds, regardless of active ingredients origin, form of pharmaceutical preparation, or market status, as long as legal procedures and requirements are satisfied. Scientific program of MKNOL, which filled three working days, traditionally accommodated 12 invited lectured, which reflected the Scientific Committee intention to cover different fields of drug discovery and development process. Regrettably, unlike in previous issues of this Journal dedicated to the conference, they are not presented in form of review articles, therefore we decided to recollect them here. Professor Jacek Kuźnicki has opened the conference with lecture on “High throughput calcium screens for identification of drug targets and drug discovery in neurodegenerative diseases”, followed by Karol L. Grela with “Olefin metathesis as an emerging tool in the synthesis of natural and bioactive compounds”, Andrzej Kutner’s “Synthetic technologies of pharmaceutical substances” and Tomasz Ciach’s “Particles for controlled drug delivery”. These contributions were accompanied by 8 oral communications and a poster session (altogether there were two sessions, comprising 140 posters!) on the first day program. The remaining part of the invited lectures list include: Bogusław A. Buszewski: “New solutions and challenges in chromatography and related techniques. Quo vadis separation techniques”; Józef Dulak: “New anti-angiogenic drugs”; Grzegorz Węgrzyn: “The use of genistein in treatment of genetic diseases”; Aleksander P. Mazurek: “Molecular properties of active ingredients – Impact on bioavailability – The biopharmaceutics classification system”; Waldemar Priebe: “Exploration of sugar-based inhibitors of glycolysis to target brain tumors”; Marcin Nowotny: “Protein crystallography as a tool in drug discovery”; Tomasz G. Wasiela: “Good Laboratory Practice as the quality system ensuring mutual acceptance of test results in the registration of pharmaceutical products”; Maciej Wieczorek: “RNAi – breakthrough technology gives hope for breakthrough therapeutics”. Although our special issue missed above listed highlights of the conference (as a consolation – full program of the 7<sup>th</sup> MKNOL is still available on [www.ifarm.waw.pl](http://www.ifarm.waw.pl)), overall response to the call for papers from authors of oral communications and posters was good. The authors will be glad to learn that finally, after years of the Editors efforts, Acta Poloniae Pharmaceutica – Drug Research has received enough recognition to be listed in the Journal Citation Reports, with an impact factor 0.347. Congratulations! There is no doubt that future interactions between MKNOL conferences and the Acta should greatly benefit from this well deserved status of the journal.

Warszawa, July 2010

Grzegorz Gryniewicz, Guest Editor